MedTrace Logo

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

NCT07338396 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-01-13

No results posted yet for this study

Summary

The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Participants will be followed for up to 5 years. During routine clinic visits, researchers will collect their TCM information (such as tongue images and pulse readings) and store small samples of their blood, stool, and tongue coating for future research.

Conditions

  • Non Small Cell Lung Cancer NSCLC

Interventions

DRUG

EGFR-TKI

Standard treatment with EGFR tyrosine kinase inhibitors (e.g., gefitinib, erlotinib, osimertinib) for NSCLC. The study observes its association with TCM syndrome patterns.

Sponsors & Collaborators

  • Beijing Chest Hospital

    collaborator OTHER

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator UNKNOWN

  • Affiliated Hospital of Xinxiang Medical University, Henan province

    collaborator UNKNOWN

  • Guangzhou University of Traditional Chinese Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2029-07-31
Completion
2031-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338396 on ClinicalTrials.gov